ArticleFrontiers in immunology2024

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US.

Yingtao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.